SCHEMBL6691401

SCHEMBL6691401

COc1ccc(-c2nc(-c3cc(OC)c(O)c(OC)c3)[nH]c2-c2ccc(OC)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 8/20 1.00
NOX1 Q9Y5S8 3/20 0.78
MAPT P10636 7/20 0.72
TP53 P04637 3/20 0.72
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
ALDH1A1 P00352 4/20 0.59
HPGD P15428 4/20 0.59
KDM4E B2RXH2 3/20 0.59
LMNA P02545 2/20 0.59
HTT P42858 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
GAA P10253 2/20 0.59
MAPK13 O15264 2/20 0.57
MAPK12 P53778 2/20 0.57
MAPK11 Q15759 2/20 0.57
MAPK14 Q16539 2/20 0.57
RAF1 P04049 1/20 0.57
NPSR1 Q6W5P4 2/20 0.57
CYP1A2 P05177 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9153583 0.91 SMPD3 (0.84) SMPD3NOX1MAPTTP53MEN1
SCHEMBL22301647 0.89 SMPD3 (1.00) SMPD3NOX1MAPTTP53MEN1
SCHEMBL6465442 0.88 NOX1 (0.81) SMPD3NOX1MAPTTP53MEN1
SCHEMBL12601823 0.88 SMPD3 (0.79) SMPD3NOX1MAPTTP53MEN1
SCHEMBL12958682 0.88 SMPD3 (1.00) SMPD3NOX1MAPTTP53MEN1
SCHEMBL11595659 0.86 SMPD3 (0.76) SMPD3NOX1MAPTTP53MEN1
SCHEMBL6465425 0.86 SMPD3 (0.76) SMPD3NOX1MAPTTP53MEN1
SCHEMBL175592 0.86 SMPD3 (0.75) SMPD3NOX1MAPTTP53MEN1
Hydrochloric Acid SCHEMBL9648176 0.85 SMPD3 (0.73) SMPD3NOX1MAPTTP53MEN1
SCHEMBL8008805 0.84 NOX1 (0.85) SMPD3NOX1MAPTTP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0347139-A2 Imidazole leuco dye composition containing 4'-hydroxyacetanilide diagnostic kit and method using same EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-12-20 EP claimed
US-4089747-A OXIDATION OF DYE-PROVIDING MATERIALS, A SULFONYL HYDRAZONE AND A COUPLER OR A TRIARYLIMIDAZOLE EASTMAN KODAK COMPANY (US) 1978-05-16 US claimed
US-20220119374-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2022-04-21 US disclosed
EP-3917530-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS The Johns Hopkins University (US) 2021-12-08 EP disclosed
WO-2020160148-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-06 WO disclosed
WO-2020160148-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-06 WO disclosed
EP-0511712-B2 Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle JOHNSON & JOHNSON CLIN DIAG (US) 2004-01-02 EP disclosed
US-6645758-B1 Polymerase Chain Reaction (PCR); use when reactions are undertaken to amplify and detect nucleic acids, using PCR technology, without exposing the environment to amplified nucleic acid JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. 2003-11-11 US disclosed
US-6475729-B1 Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. 2002-11-05 US disclosed
EP-0603954-B1 Immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer JOHNSON & JOHNSON CLIN DIAG (US) 2000-03-08 EP disclosed
US-5888723-A SENSITIVE HYBRIDIZATION ASSAY USING NUCLEIC ACID REAGENT COMPOSED OF OLIGONUCLEOTIDES COVALENTLY ATTACHED TO POLYMER PARTICLES WHICH ARE ADHERED TO SUPPORT USING WATER INSOLUBLE ADHESIVE; LOW BACKGROUND JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1999-03-30 US disclosed
WO-1989009939-A1 COMPOSITIONS, DIAGNOSTIC KIT AND METHOD FOR RAPID DETECTION OF ANTIBODIES EASTMAN KODAK COMPANY (US) 1989-10-19 WO disclosed
EP-0337785-A1 Diagnostic kit and method for rapid detection of antibodies Johnson & Johnson Clinical Diagnostics, Inc. (US) 1989-10-18 EP disclosed
US-4870007-A DIAGNOSIS OF PREGNANCY EASTMAN KODAK COMPANY (US) 1989-09-26 US disclosed
EP-0328413-A2 Sodium decyl sulfate wash solution, test kit and method for the determination of an immunological ligand EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-08-16 EP disclosed
EP-0328388-A2 Wash solution, test kit and method for the determination of an immunological ligand EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-08-16 EP disclosed
EP-0321261-A1 Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-06-21 EP disclosed
EP-0318255-A2 Cuvette EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-05-31 EP disclosed
EP-0308236-A2 Dye-providing composition, diagnostic test kit and their use in method for ligand determination using peroxidase labeled-receptor Johnson & Johnson Clinical Diagnostics, Inc. (US) 1989-03-22 EP disclosed
EP-0302715-A1 Avidin- and biotin-immobilized reagents, analytical elements and methods of use EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119374-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS SMPD2, SPTLC2, SGMS2 SMPD3 8/4885NOX1 2182/4885MAPT 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.